Phase 2 N=54 Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease
Graft vs Host Disease
Primary: Participants That Developed Severity Score 3 or Higher Oral Chronic Graft Versus Host Disease (GVHD). — 7; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=550 Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) up to 28 Days After Study Treatment Discontinuation — 527 Participants
N/A N=666 COVID-19 and the Healthy Minds Program for Educators
Anxiety · Depression · Psychological Stress
Primary: Change From Baseline on an Aggregate Measure of Psychological Distress That Averages the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety and…
Phase 2 N=67 Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) — 30; 30 percentage of participants
Phase 3 N=598 Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase. — 91.6; 90.7 Percentage of…
Phase 2 N=110 A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Lymphoma
Primary: Objective Response Rate (ORR) Based on Lugano Classification Criteria — 50.0; 33.3; 57.1; 58.3 percentage of participants
Phase 3 N=165 A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache
Episodic Cluster Headache · Chronic Cluster Headache
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) — 119; 17 Participants
N/A N=18 Cryo Balloon for Residual Barrett's Esophagus
Barrett's Esophagus
Primary: Eradication of Barrett's Esophagus — 2 Participants
N/A N=6,030 Optimizing Electronic Alerts for Acute Kidney Injury
Acute Kidney Injury
Primary: Composite of Progression of AKI, Inpatient Dialysis, or Inpatient Death — 622; 653 Participants — p=0.67
N/A N=1,502 Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
Diabetes Mellitus, Type 2
Primary: Number of Participants With Ketoacidosis — 1; 1 Participants
N/A N=170 CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)
Persistent Atrial Fibrillation
Primary: Primary Efficacy Endpoint - Number of Participants to Achieve Freedom From AF/AT/AFL. — 67; 25 Participants — p=0.0472
Phase 2 N=161 A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
Lymphoma
Primary: Objective Response Rate (ORR) — 8.3; 39.0; 64.5; 71.4 percentage of participants
Phase 2 N=126 A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma
Lymphoma
Primary: Objective Response Rate With Parsaclisib Based on Lugano Classification Response Criteria — 65.2; 77.7 percentage of participants
Phase 2 N=31 Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
Metastatic Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Progression-free Survival (PFS) — 2.5 months
Phase 2 N=32 Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
Hypercholesterolemia
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 3; 5 Participants